Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer

NCT ID: NCT01116713

Last Updated: 2010-05-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-06-30
• Study Completion Date: 2010-05-31

Brief Summary

Postoperative pain, nausea and vomiting (PONV) are the most common complications after anesthesia and surgery. Women undergoing mastectomy with axillary dissection are at a particularly high risk for the development of PONV and an incidence of 60-80% in patients receiving no antiemetic has been reported. Emetic episodes predispose to aspiration of gastric contents, wound dehiscence, psychological distress, and delayed recovery and discharge times. These justify the use of prophylactic antiemetics in women scheduled for mastectomy. Most of the currently used antiemetics, including antihistamines, butyrophenones and dopamine receptor antagonists have been reported to cause occasional undesirable adverse effects, such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations and extrapyramidal signs. Antiserotonins (e.g., ondansetron) are available for the prevention and treatment of PONV in patients undergoing various types of surgery [4]. However, the use of prophylactic antiemetic therapy with antiserotonins has been criticized for being too expensive.

Dexamethasone was first reported to be an effective antiemetic regimen in patients receiving cancer chemotherapy.

The purpose of this study was to evaluate the efficacy of dexamethasone treatment for reducing pain and PONV as well as analgesic and antiemetic requirements in women undergoing general anesthesia for mastectomy with axillary lymph node dissection.

Detailed Description

Breast cancer is the most frequent malignant neoplasm worldwide. In emerging countries such as Mexico, there has been an increase in its frequency and mortality [1, 2] and it is the second most frequent neoplasm after cervical carcinoma. Between 25,000 and 30,000 new cases are diagnosed annually. Unfortunately, only a few women have regular mammography screening so the proportion of patients with locally advanced disease at diagnosis is high. In 2003, only 5-10% of newly diagnosed cases in Mexico were clinical stages 0 or I [2]. Surgical resection with axillary lymph node dissection constitutes the treatment of choice associated with neoadjuvant therapy and postoperative chemotherapy and/or radiation therapy.

Postoperative pain, nausea and vomiting (PONV) are the most common complications after anesthesia and surgery. Women undergoing mastectomy with axillary dissection are at a particularly high risk for the development of PONV and an incidence of 60-80% in patients receiving no antiemetic has been reported. Emetic episodes predispose to aspiration of gastric contents, wound dehiscence, psychological distress, and delayed recovery and discharge times. These justify the use of prophylactic antiemetics in women scheduled for mastectomy. Most of the currently used antiemetics, including antihistamines, butyrophenones and dopamine receptor antagonists have been reported to cause occasional undesirable adverse effects, such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations and extrapyramidal signs. Antiserotonins (e.g., ondansetron) are available for the prevention and treatment of PONV in patients undergoing various types of surgery. However, the use of prophylactic antiemetic therapy with antiserotonins has been criticized for being too expensive.

Dexamethasone was first reported to be an effective antiemetic regimen in patients receiving cancer chemotherapy. Some authors have reviewed the available randomized trials (1996-2001) regarding perioperative single-dose steroid administration and found that dexamethasone had antiemetic and analgesic effects in various types of operations. One ot this studies demostrated that intravenous dexamethasone at 4 mg was effective for the prevention of PONV following breast surgery but they could not demonstrate any difference in postoperative pain.

The purpose of this study was to evaluate the efficacy of dexamethasone treatment for reducing pain and PONV as well as analgesic and antiemetic requirements in women undergoing general anesthesia for mastectomy with axillary node dissection.

Patients and Methods Patients Between June and August 2009, 70 patients undergoing mastectomy with axillary dissection were studied in a prospective, randomized, double-blind clinical trial. Patients were randomized to receive intravenous dexamethasone (8 mg) or homologated placebo 60 minutes before skin incision, using an equal number of blinded envelopes. Patients of American Society of Anesthesiologists classes III and IV were excluded. Further exclusion criteria were age more than 80 years; pregnancy; active menstruation; treatment with steroids; severe diabetes mellitus (serum HbA1c > 8%); use of opioids, sedatives or any kind of analgesics less than one week before mastectomy, or a history of alcohol or drug abuse. Patients with any history of motion sickness and ⁄or previous PONV after any surgical procedure were excluded. All patients were admitted to the hospital one day before the operation and were followed from hospital admission until 30 days after the surgical procedure to detect any medical or surgical morbidity.

Anesthesia and surgery All patients underwent a standardized general anesthesia procedure and none of them received any preanesthetic medication. Induction used intravenous propofol (2 mg/kg body weight) and fentanyl (3-5 mcg/kg). Vecuronium bromide (0.1 mg/kg) was used to facilitate tracheal intubation. Anesthesia was maintained with 2-3% sevoflurane and 66% nitrous oxide in oxygen. Ventilation was controlled mechanically and maintained constant throughout surgery using an anesthetic and respiratory gas analyzer for monitoring.

All patients were monitored with indirect determinations of arterial pressure and heart rate using standard techniques, as well as the expired CO2 content and oxygen blood saturation. Afterwards, all patients were extubated and transferred to the immediate postsurgical care unit with cardiovascular and oxygen monitoring.

Surgical procedures All patients were treated according to the preoperative clinical stage with radical mastectomy or breast conservative surgery with lymph node axillary dissection by the same surgical team. In all patients, closed suction drains were placed in the region subjected to surgery and were removed during the following days. Chemotherapy and/or radiotherapy were administered 3-4 weeks after uncomplicated surgical resections.

Analgesia and antiemetic therapies Pain was assessed immediately on return to the recovery room and at 6, 12 and 24 h after the operation using a visual analogue scale (VAS; 0 = no pain to 10 = most severe pain). Analgesia was given as intravenous sodium ketorolac (30 mg every 8 hours) and intravenous tramadol infusion (50 mg) was used as a backup analgesic medication. The incidence of PONV was recorded immediately on return to the recovery room and at 6, 12 and 24 h after the operation, using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 = vomiting). Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit, retching was defined as the labored, spasmodic, rhythmic contraction of the respiratory muscles without the expulsion of gastric contents, and vomiting was defined as the forceful expulsion of gastric contents from the mouth. Intravenous ondansetron (4-8 mg) was given for antiemetic treatment on demand.

Data collection and statistical analysis Postoperative complications were recorded during hospitalization and the patients were followed up to 30 days after discharge. Additional data collected included patient age, body mass index (BMI), any history of smoking and neoadjuvant chemotherapy, anesthesia and operation time and the frequency of use of analgesic and antiemetic drugs. These parameters were summed and compared between the dexamethasone and placebo groups.The study endpoints were postoperative nausea and vomiting, and pain measured by the VAS and the need for additional analgesic and antiemetic drugs.

The sample size was predetermined. We expected a 35% difference in the incidence of nausea and vomiting between groups. The alpha error was set at 0.05 and beta error at 0.20; n = 35 patients for each group was considered adequate, according to a power analysis. Results are expressed as percentages and as the mean ± standard deviation (SD). Student's t test, the Chi-squared test or Fisher's Exact Test were used for the analysis of quantitative and qualitative data, respectively. Differences were considered statistically significant at p < 0.05.

Ethical considerations The study was conducted according to the principles of the Declaration of Helsinki of 1989 and the Mexican Health Guidelines. The Ethical and Research Committees of the Oncologic Institute, approved all protocols. Full, written informed consent was obtained from all patients before their inclusion in the study.

Conditions

Postoperative Pain; Postoperative Nausea; Postoperative Vomiting

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Dexamethasone group

This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.

Group Type: ACTIVE_COMPARATOR

intravenous dexamethasone

Intervention Type: DRUG

One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.

Placebo group

Patients of these group received homologated placebo 60 minutes before skin incision.

Group Type: PLACEBO_COMPARATOR

Homologated placebo.

Intervention Type: DRUG

Patients of the control group received homologated placebo 60 minutes before skin incision

Interventions

intravenous dexamethasone

One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.

Intervention Type: DRUG

Homologated placebo.

Patients of the control group received homologated placebo 60 minutes before skin incision

Intervention Type: DRUG

Other Intervention Names

no other intervention; no other intervention

Eligibility Criteria

Inclusion Criteria

• American Society of Anesthesiologists classes I-II female patients with breast cancer scheduled for surgical treatment; mastectomy plus axillary node dissection.

Exclusion Criteria

• American Society of Anesthesiologists classes III and IV.
• Age more than 80 years; pregnancy; active menstruation; treatment with steroids; severe diabetes mellitus (serum HbA1c > 8%); use of opioids, sedatives or any kind of analgesics less than one week before mastectomy, or a history of alcohol or drug abuse.
• Patients with any history of motion sickness and or previous postoperative nausea and vomiting after any surgical procedure.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Instituto Mexicano del Seguro Social

OTHER_GOV

Sponsor Role: lead

Responsible Party

Mexican Institute of Social Security

Principal Investigators

Alejandro Gonzalez-Ojeda, M.D., Ph.D.

Role: STUDY_DIRECTOR

Instituto Mexicano del Seguro Social

Locations

Breast Clinic. Oncologic Institute of Jalisco

Guadalajara, Jalisco, Mexico

Research Unit in Clinical Epidemiology, Specialties Hospital. Mexican Institute of Sociaql Security

Guadalajara, Jalisco, Mexico

Countries

Mexico

References

Gomez-Hernandez J, Orozco-Alatorre AL, Dominguez-Contreras M, Oceguera-Villanueva A, Gomez-Romo S, Alvarez Villasenor AS, Fuentes-Orozco C, Gonzalez-Ojeda A. Preoperative dexamethasone reduces postoperative pain, nausea and vomiting following mastectomy for breast cancer. BMC Cancer. 2010 Dec 23;10:692. doi: 10.1186/1471-2407-10-692.

Reference Type: DERIVED

PMID: 21182781 (View on PubMed)

Other Identifiers

Dxt-2010-breast cancer

Identifier Type: -

Identifier Source: org_study_id